MyHeritage Releases Groundbreaking Feature to Animate the Faces in Still Photos
25.2.2021 17:54:00 EET | Business Wire | Press release
MyHeritage, the leading global service for discovering your past and empowering your future, announced today the release of Deep Nostalgia™, a new feature that animates the faces in still photos. Deep Nostalgia™ gives family history a fresh new perspective by producing a realistic depiction of how a person could have moved and looked if they were captured on video. MyHeritage is the only company to offer a complete suite of features for colorizing, restoring, enhancing, and now animating historical photos.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210225005747/en/
Introducing Deep Nostalgia™ (Photo: Business Wire)
The technology for animating the faces in photos was licensed by MyHeritage from D-ID, a company that specializes in video reenactment using deep learning. Deep Nostalgia™ uses several pre-recorded driver videos prepared by MyHeritage, which direct the movements in the animation and consist of sequences of real human gestures. A preferred driver is automatically selected for each face based on its orientation, and then seamlessly applied to the photo. The result is a short, high-quality video animation of an individual face that can smile, blink, and move. To achieve optimal results, the photos are enhanced prior to animation using the MyHeritage Photo Enhancer, which brings blurry and low-resolution faces into focus and increases their resolution.
Deep Nostalgia™ is the newest AI-based photo tool on MyHeritage, and comes on the heels of two highly-acclaimed features that the company released last year, the MyHeritage Photo Enhancer and MyHeritage In Color™, which colorizes black and white photos and was recently expanded to also restore the colors in faded color photos. These features have gone viral and have been used over 30 million times. MyHeritage keeps building on that momentum by adding new, cutting-edge tools for historical photos that inspire a fresh appreciation for family history and nostalgic family photos.
“You’ll have a ‘wow moment’ when you see a treasured family photo come to life with Deep Nostalgia™,” said Gilad Japhet, Founder and CEO of MyHeritage. “Seeing our beloved ancestors’ faces come to life in a video simulation lets us imagine how they might have been in reality, and provides a profound new way of connecting to our family history.”
“This new product integration is an exciting collaboration between two innovative companies,” said Gil Perry, Co-Founder and CEO of D-ID. “We’re thrilled that our technology will be accessible to millions of people on MyHeritage and hope many of them will enjoy the impact of video reenactment for historical photos.”
Integration into the MyHeritage platform
Deep Nostalgia™ is a freemium feature on MyHeritage. Users can animate several photos for free, regardless of the number of faces in the photo. Beyond that, continued use requires a subscription. The video animation can easily be shared with family and friends on Facebook, Twitter, WhatsApp, and other social media.
About MyHeritage
MyHeritage is the leading global discovery platform for exploring family history. With billions of historical records and family tree profiles, and with sophisticated matching technologies that work across all its assets, MyHeritage allows users to discover their past and empower their future. MyHeritage DNA is one of the world’s largest consumer DNA databases, with more than 4.7 million customers. MyHeritage is the most popular DNA test and family history service in Europe. Since 2020, MyHeritage is home to the world’s best AI technologies for enhancing and colorizing historical photos. www.myheritage.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210225005747/en/
Contact information
MyHeritage
Rafi Mendelsohn
Director of PR & Social Media
Phone: 917-725-5018
Email: pr@myheritage.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom